NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-22-174 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Funding Opportunity PAR-22-173 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Funding Opportunity RFA-AG-23-033 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications seeking to develop novel, transformative artificial intelligence/machine learning (AI/ML) strategies, and computer automation, to integrate, extract, and interpret multi-omic (i.e., genome, epigenome, transcriptome, proteome, metabolome, microbiome, phenome) data sets from human exceptional longevity (EL) cohorts and multiple non-human species that display wide variation in life span and decipher the relationships between DNA, RNA, proteins, metabolites, and other cell variables, as well as links to disease risks and exceptionally healthy aging. The investigative team(s) for this FOA is/are expected to be multi-disciplinary, encompassing expertise in AI/ML and a variety of disciplines, including, but not limited to, aging biology, comparative biology, and bio/chemo informatics. This FOA utilizes the National Institutes of Health's Phased Innovation Award (R21/R33) funding mechanism. During the R21 phase, investigative teams will design and develop intelligent and innovative algorithms and novel AI/ML based computational strategies. During the R33 phase, teams will apply the developed AI/ML tools to complex, heterogenous multi-omic data sets from exceptional healthy aging human cohorts and non-human species to discover novel protective molecular factors that influence EL, and to develop translational strategies on omic based therapeutic target(s) to prevent, or delay, age-related diseases, including Alzheimers disease (AD) and AD-related dementia (ADRD), and enhance human health span.
Notice NOT-TR-22-032 from the NIH Guide for Grants and Contracts
Funding Opportunity PAS-22-196 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Innovation Research (SBIR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services that have the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.
Notice NOT-OD-22-135 from the NIH Guide for Grants and Contracts
Notice NOT-DA-22-062 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-092 from the NIH Guide for Grants and Contracts
Notice NOT-DA-22-063 from the NIH Guide for Grants and Contracts
Notice NOT-DC-22-009 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAS-22-197 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Technology Transfer Research (STTR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services with the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.
Notice NOT-CA-22-093 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-23-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to solicit applications for pragmatic clinical trials to decrease or prevent negative clinical outcomes due to vascular contributions to cognitive impairment and dementia (VCID), including locally representative NIH defined populations that experience health disparities in dementia. Examples of responsive projects and interventions that affect VCID outcomes include, but are not limited to, blood pressure control implementation; lifestyle modification using aerobic exercise; and early detection and treatment of VCID risk factors.
Notice NOT-HG-22-029 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-147 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-110 from the NIH Guide for Grants and Contracts
Notice NOT-ES-22-011 from the NIH Guide for Grants and Contracts
Notice NOT-ES-22-012 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-039 from the NIH Guide for Grants and Contracts